MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - May 30, 2012) -
MorphoSys AG /
MorphoSys Announces New Management Appointments
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
has strengthened its management in two positions. Charlotte Lohmann
Company as General Counsel, and Martin Clark as Head of Central
Charlotte Lohmann joins MorphoSys after eleven years at Wilex AG where
most recently Senior Vice President Legal Affairs & Human Resources.
her position at Wilex, she practiced as a lawyer at the law firm KPMG
Goerdeler GmbH in Munich. She started her career in the tax and law
of the auditing company KPMG Deutsche Treuhand-Gesellschaft AG in the
office. Mrs. Lohmann received her degree in law from the University of
and is a licensed attorney.
Martin Clark joins MorphoSys from Sandoz Biopharmaceuticalswhere he
delivery of projects via third party contract research organizations as
Clinical Operations and Third Party Management. He has over 30 years
in the pharmaceutical industry filling both scientific and management
with Basilea, Serono, Merck-Serono, Novartis and Pfizer.
"We are very pleased to welcome outstanding individuals for two
positions within the MorphoSys Group," explained Dr. Simon Moroney,
Executive Officer of MorphoSys AG. "These additions will further
complement our existing management team, and will help us to continue to
MorphoSys as a leading biopharmaceutical company."
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®,
RapMAT® and arYla® are registered trademarks of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE